On Friday, Wells Fargo & Co (NYSE:WFC)’s shares declined -1.90% to $53.31.
Wells Fargo & Company (NYSE: WFC) has promoted Cavan Harris to regional vice president of its Charlotte West Commercial Banking team that covers Charlotte and western North Carolina middle market companies with annual revenues of $20 million and above.
An 18-year company veteran, Harris began his banking career in corporate banking with Wells Fargo predecessor, Wachovia Bank, in Gastonia, N.C. where he supported senior relationship managers who served western North Carolina, principally Gastonia, Hickory and Asheville. He joined the Commercial Banking team in Charlotte in August 2001, where he was promoted to a relationship manager and later to a senior relationship manager. Harris most recently served as a Commercial Banking relationship manager group leader for the Metro Charlotte Commercial Banking team in Charlotte, a role he held since 2010.
“Cavan is a seasoned financial professional with deep roots throughout Charlotte and western North Carolina,” said Suzanne Morrison, head of Wells Fargo Commercial Banking’s Carolinas Division. “His strong background in serving our commercial customers and his tenure of leadership in the region will be invaluable in assisting middle-market companies succeed financially.”
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Exelon Corporation (NYSE:EXC)’s shares dropped -2.06% to $25.93.
Nearly 5,000 Chicago fifth grade students are becoming Super Energy Savers through a joint education program offered by ComEd and Peoples Gas. Super Savers, a FREE science, engineering and mathematics (STEM) based curriculum, developed for fifth grade students, will teach thousands of students about the importance of energy efficiency, and equip them to share money- and energy-saving tips with their families.
The annual program launched recently at Jose de Diego Community Academy, located on Chicago’s near north side, where Commissioner Miguel del Valle of the Illinois Commerce Commission (ICC) and representatives from ComEd and Peoples Gas were on-hand to deliver Super Savers kits to the school’s fifth grade students.
Jose de Diego fifth grade teacher Pam Alexandroff believes the program is a fun and educational way to get kids to think about concrete ways they can assist the environment. “The Super Savers Program is a fun, practical way for kids to teach their own families how to save energy at home,” she said. “They can see for themselves how small steps can lead to big changes in energy usage.”
Commonwealth Edison Company (ComEd) is a unit of Chicago-based Exelon Corporation (EXC).
Exelon Corporation, a utility services holding company, engages in the energy generation and delivery businesses in the United States. It owns electric generating facilities, such as nuclear, fossil, and hydroelectric generation facilities, in addition to wind and solar photovoltaic facilities.
At the end of Friday’s trade, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)‘s shares dipped -6.45% to $53.95.
Isis Pharmaceuticals, Inc. (ISIS) declared that its partner, Biogen, has initiated a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS). ISIS-SOD1Rx is part of Isis’ planned partnership with Biogen to discover and develop antisense drugs to treat neurological diseases. ISIS-SOD1Rx, formerly referred to as ISIS-BIIB3Rx, is a Gen. 2.0+ antisense drug designed to reduce the production of superoxide dismutase 1 (SOD1). A mutation in the SOD-1 gene results in an inherited form of ALS, referred to as SOD1-ALS. SOD1-ALS is the second most common familial form of ALS, accounting for up to 20 percent of familial ALS. Familial ALS represents about 10 percent of all cases of ALS. Presently, treatment options for patients with ALS are extremely limited with no drugs that significantly slow disease progression.
“There is substantial evidence that mutations in the SOD1 gene are responsible for a toxic gain of function that can lead to progressive loss of motor neurons in patients with SOD1-ALS. As a result, patients with SOD1-ALS experience muscle weakness, loss of movement, difficulty in breathing and swallowing and eventually succumb to their disease. Our antisense technology provides us with the unique ability to act at the genetic level to reduce the production of the SOD1 protein, counting the mutant SOD1 protein that is believed to be the cause of the disease,” said C. Frank Bennett, Ph.D., senior vice president of research at Isis Pharmaceuticals. “We have formerly demonstrated that we can safely administer an antisense drug in patients with familial ALS by intrathecal injection. In the study initiated recently, we are evaluating a more potent antisense drug designed to directly reduce the production of the SOD1 protein. This approach has the potential to provide therapeutic benefit to patients with SOD1-ALS by slowing or even halting progression of this fatal disease.”
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product comprises the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, counting cardiovascular and metabolic diseases; severe and rare diseases, which comprise neurological disorders; and cancer.